Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
ClinicalTrials.gov study NCT02378389. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
ClinicalTrials.gov study NCT02339532. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
ClinicalTrials.gov study NCT01598077. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
ClinicalTrials.gov study NCT01271920. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
ClinicalTrials.gov study NCT05063786. IPD Sharing: NO. Countries: 6. Publications: 1.
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT00938652. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
ClinicalTrials.gov study NCT05132582. IPD Sharing: YES. Countries: 23. Publications: 1.
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT00047255. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT03225937. IPD Sharing: NO. Countries: 1. Publications: 3.
REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab
ClinicalTrials.gov study NCT02688998. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
ClinicalTrials.gov study NCT05346224. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
ClinicalTrials.gov study NCT03013504. IPD Sharing: NO. Countries: 13. Publications: 2.
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Riboci
ClinicalTrials.gov study NCT06311383. IPD Sharing: NO. Countries: 1. Publications: 1.
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
ClinicalTrials.gov study NCT03368196. IPD Sharing: YES. Countries: 1. Publications: 0.
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
ClinicalTrials.gov study NCT03756064. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
ClinicalTrials.gov study NCT04647916. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
ClinicalTrials.gov study NCT05710666. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00807859. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
ClinicalTrials.gov study NCT03176238. IPD Sharing: YES. Countries: 13. Publications: 0.
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
ClinicalTrials.gov study NCT04576143. IPD Sharing: NO. Countries: 1. Publications: 7.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.